Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Migration, Crosslink

📖

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-sgc-stimulator-therapy

📖 Wiki Page

therapeutic1233 wordssynced 2026-04-02

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Soluble Guanylate Cyclase (sGC) Stimulator Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">sGC enzyme</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">PKG</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">cGMP-dependent phosphodiesterases</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Approval Year</td>
</tr>
<tr>
<td class="label">Riociguat (Adempas)</td>
<td>2013</td>
</tr>
<tr>
<td class="label">Vericiguat (Verquvo)</td>
<td>2021</td>
</tr>
<tr>
<td class="label">System</td>
<td>Adverse Effect</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Hypotension</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Headache</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Dizziness</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea</td>
</tr>
<tr>
<td class="label">Hematologic</td>
<td>Anemia</td>
</tr>
</table>

...

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Soluble Guanylate Cyclase (sGC) Stimulator Therapy</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">sGC enzyme</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">PKG</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">cGMP-dependent phosphodiesterases</td>
<td>Modulation</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Inhibition</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Approval Year</td>
</tr>
<tr>
<td class="label">Riociguat (Adempas)</td>
<td>2013</td>
</tr>
<tr>
<td class="label">Vericiguat (Verquvo)</td>
<td>2021</td>
</tr>
<tr>
<td class="label">System</td>
<td>Adverse Effect</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Hypotension</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Headache</td>
</tr>
<tr>
<td class="label">Cardiovascular</td>
<td>Dizziness</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea</td>
</tr>
<tr>
<td class="label">Hematologic</td>
<td>Anemia</td>
</tr>
</table>

Soluble guanylate cyclase (sGC) stimulators represent a novel therapeutic class that directly activate the nitric oxide (NO)-sGC-cGMP pathway. These compounds, including riociguat and vericiguat, have shown promise in cardiovascular disease and are being investigated for potential neuroprotective effects in neurodegenerative disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [@evgenov2006]

Mechanism of Action

Direct sGC Activation

sGC stimulators work by binding directly to the heme moiety of soluble guanylate cyclase, stabilizing the enzyme in its active conformation. This leads to increased production of cyclic guanosine monophosphate (cGMP) from GTP. [@stasch2011]

Mermaid diagram (expand to render)

Key Molecular Targets

Therapeutic Potential in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, sGC stimulators may address several key pathological mechanisms: [@sullivan2022]

Cerebral Blood Flow Dysfunction: AD is associated with impaired cerebral autoregulation and reduced cerebral blood flow. cGMP promotes vasodilation of cerebral vessels through protein kinase G activation, potentially improving cerebral perfusion.

Oxidative Stress: The NO-sGC-cGMP pathway has antioxidant properties. cGMP can upregulate expression of antioxidant enzymes and reduce reactive oxygen species (ROS) accumulation.

Amyloid Pathology: Preclinical studies suggest cGMP signaling may influence amyloid precursor protein (APP) processing and amyloid-beta (Aβ) clearance.

Tau Pathology: cGMP-dependent signaling may affect tau phosphorylation through modulation of various kinases and phosphatases.

Parkinson's Disease

In PD, sGC stimulators may offer neuroprotection through: [@thal2018]

Dopaminergic Neuron Survival: cGMP promotes survival of dopaminergic neurons through activation of prosurvival signaling pathways.

Mitochondrial Function: The cGMP pathway can enhance mitochondrial biogenesis and function, addressing mitochondrial dysfunction in PD.

Neuroinflammation: sGC activation has anti-inflammatory effects in the central nervous system, potentially modulating microglial activation.

Alpha-Synuclein Pathology: Emerging evidence suggests cGMP signaling may influence alpha-synuclein aggregation and clearance.

Amyotrophic Lateral Sclerosis (ALS)

sGC stimulators are being investigated in ALS for: [@nagai2019]

Motor Neuron Protection: cGMP-dependent signaling promotes survival of motor neurons under stress conditions.

Vascular Dysfunction: ALS is associated with vascular abnormalities; improving blood flow may provide neuroprotective benefits.

Glutamate Excitotoxicity: The cGMP pathway can modulate glutamatergic signaling, potentially reducing excitotoxic damage.

Clinical Development Status

FDA-Approved sGC Stimulators

Clinical Trials in Neurodegeneration

As of 2024, sGC stimulators remain in preclinical investigation for neurodegenerative diseases. Several Phase I/II trials are planned or recruiting to evaluate: [@sweeney2023]

Safety and tolerability in patient populations
Biomarker endpoints (cerebrospinal fluid cGMP, neuroimaging markers)
Cognitive/functional outcomes

Preclinical Evidence

Animal Models

Multiple preclinical studies have demonstrated neuroprotective effects of sGC stimulators: [@kalia2015]

Stroke Models: Riociguat reduced infarct size and improved functional recovery in rodent stroke models.

AD Models: In APP/PS1 transgenic mice, sGC activation improved cognitive function and reduced amyloid burden.

PD Models: In MPTP-induced parkinsonian mice, sGC stimulators protected dopaminergic neurons.

ALS Models: In SOD1 transgenic mice (ALS model), sGC activation delayed disease progression.

In Vitro Studies

Cell culture studies have shown: [@van2020]

Protection against oxidative stress-induced neuronal death
Reduction in inflammatory cytokine production by microglia
Improved mitochondrial function
Enhanced autophagy

Safety Profile

Common Adverse Effects

Based on cardiovascular trials: [@massion2005]

Drug Interactions

Nitrates: Contraindicated due to severe hypotension
PDE-5 Inhibitors: Avoid combination
Antihypertensives: May enhance blood pressure lowering

Special Populations

Renal Impairment: Dose adjustment may be needed
Hepatic Impairment: Caution advised
Elderly: No specific dose adjustment

Research Gaps and Future Directions

BBB Penetration: Further studies needed on central nervous system penetration of sGC stimulators

Optimal Dosing: Neuroprotective dosing regimens remain to be established

Biomarkers: Validated biomarkers for monitoring treatment response needed

Combination Therapy: Potential synergies with other therapeutic approaches

Disease-Modifying Potential: Long-term studies needed to assess disease modification

Cross-References

Innate Immune Signaling Pathways in Alzheimer's Disease
Insulin Resistance and Metabolic Dysfunction in Alzheimer's Disease
Mitochondrial Dynamics

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Cerebral Amyloid Angiopathy (CAA](/mechanisms/dopaminergic-neuron-vulnerability)

Cerebral Cortex — Primary target region

External Links

[sGC (Wikipedia)](https://en.wikipedia.org/wiki/Guanylate_cyclase)
[cGMP (Wikipedia)](https://en.wikipedia.org/wiki/Cyclic_guanosine_monophosphate)
[Nitric Oxide (Wikipedia)](https://en.wikipedia.org/wiki/Nitric_oxide)

References

[Evgenov et al., Nat Rev Drug Discov (2006) — sGC stimulators: a novel therapeutic approach (2006)](https://pubmed.ncbi.nlm.nih.gov/16685149/)

[Stasch et al., Pharmacol Ther (2011) — sGC stimulators and activators (2011)](https://pubmed.ncbi.nlm.nih.gov/21377088/)

[Ghofrani et al., N Engl J Med (2013) — Riociguat for CTEPH (2013)](https://pubmed.ncbi.nlm.nih.gov/23682256/)

[Armstrong et al., N Engl J Med (2020) — Vericiguat in heart failure (2020)](https://pubmed.ncbi.nlm.nih.gov/31995684/)

[Liu et al., J Cereb Blood Flow Metab (2014) — sGC and cerebral blood flow (2014)](https://pubmed.ncbi.nlm.nih.gov/24300248/)

[K害人 et al., Neurobiol Aging (2017) — cGMP signaling in AD models (2017)](https://pubmed.ncbi.nlm.nih.gov/28284708/)

[Zhang et al., J Neurosci (2020) — sGC activation and neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32296018/)

[Bivalacqua et al., Free Radic Biol Med (2019) — Oxidative stress and sGC (2019)](https://pubmed.ncbi.nlm.nih.gov/30685512/)

[Sullivan et al., Mov Disord (2022) — sGC in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35072219/)

[Thal et al., Brain (2018) — cGMP and tau pathology (2018)](https://pubmed.ncbi.nlm.nih.gov/29474625/)

[Nagai et al., J Neurochem (2019) — sGC and neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/30628765/)

[Mullard et al., Nat Rev Neurol (2021) — Emerging therapies for neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34050376/)

[Tong et al., Ann Neurol (2020) — Motor neuron protection by cGMP (2020)](https://pubmed.ncbi.nlm.nih.gov/32412683/)

[Kelley et al., Pharmacol Res (2022) — sGC in ALS models (2022)](https://pubmed.ncbi.nlm.nih.gov/35093429/)

[Lang et al., J Clin Invest (2021) — Cerebrovascular dysfunction in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34043529/)

[Sweeney et al., Nat Rev Dis Primers (2023) — Alzheimer's disease mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/36797224/)

[Unknown, Kalia & Lang, Lancet (2015) — Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904345/)

[Van Schependael et al., JACC Basic Transl Sci (2020) — sGC pharmacology (2020)](https://pubmed.ncbi.nlm.nih.gov/32766521/)

[Massion et al., Pharmacol Rev (2005) — sGC as therapeutic target (2005)](https://pubmed.ncbi.nlm.nih.gov/15985712/)

[Unknown, Hobbs & Hunter, Nat Rev Drug Discov (2020) — sGC modulators clinical development (2020)](https://pubmed.ncbi.nlm.nih.gov/32341075/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-sgc-stimulator-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-sgc-stimulator-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f962434fdb99
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-sgc-stimulator-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

41

Outgoing

79

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

Mechanism of Action

Direct sGC Activation

Key Molecular Targets

Therapeutic Potential in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Clinical Development Status

FDA-Approved sGC Stimulators

Clinical Trials in Neurodegeneration

Preclinical Evidence

Animal Models

In Vitro Studies

Safety Profile

Common Adverse Effects

Drug Interactions

Special Populations

Research Gaps and Future Directions

Cross-References

See Also

External Links

References

💬 Discussion

📗 Cite This Artifact

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

Soluble Guanylate Cyclase (sGC) Stimulator Therapy

Overview

Mechanism of Action

Direct sGC Activation

Key Molecular Targets

Therapeutic Potential in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Clinical Development Status

FDA-Approved sGC Stimulators

Clinical Trials in Neurodegeneration

Preclinical Evidence

Animal Models

In Vitro Studies

Safety Profile

Common Adverse Effects

Drug Interactions

Special Populations

Research Gaps and Future Directions

Cross-References

Related Mechanisms

Related Diseases

Related Brain Regions

See Also

External Links

References

Related Hypotheses

💬 Discussion